COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to a diverse group of coronaviruses characterized by enveloped, single-stranded, positive sense ribonucleic acid (RNA) viruses with a long-range tropism, which gives them the ability to cause overwhelming diseases ^[1][7].

Viruses are known to enter the host cell with the help of receptors that mediate endocytosis. In the case of SARS-CoV-2, it has been reported that the spike protein is responsible for binding to the angiotensin-converting enzyme 2 (ACE-2) receptor on the host cell surface, which is the entry point for the virus. However, SARS-CoV-2 entry is not only dependent on the binding of the spike protein to the ACE-2 receptor, but it also requires the priming of the spike protein by the serine-2 transmembrane protease (TMPRSS2), which is crucial for the fusion of the virus to the host cell membrane. This synergy between the ACE-2 receptor and TMPRSS2 is necessary for the virus to enter into the host. The expression of TMPRSS2 is much higher than the ACE-2 receptor, suggesting that the latter is the limiting factor for SARS-CoV-2 during the early stage of infection ^[2][3][8,9].

Evidence has shown that the first target of the virus is the respiratory system. However, it can cause alterations in different body organs. Although some patients are asymptomatic or have mild to moderate symptoms, a percentage can develop severe illness ^[4][10]. The most common complications are acute respiratory failure syndrome (ARDS), septic shock, and sepsis. Risk factors such as age and comorbidities such as chronic diseases are related to severe illness and mortality ^[5][2].

Several symptoms have been associated with this disease, such as fever, cough, difficulty in breathing, headache, fatigue, sore throat, rhinorrhea, anorexia, myalgias, diarrhea, and in severe cases, pneumonia. The primary transmission mode is from person to person, through inhalation of the droplets released when coughing or sneezing. In general, symptomatic people are more contagious. However, transmission is also possible through fomites ^[5][2].

Moreover, it is valuable to mention that viruses are susceptible to mutations leading to the potential development of new variants. In response to the emergence of new SARS-CoV-2 variants, WHO has classified the variants according to the Greek alphabet (e.g., Alpha, Beta, Gamma, and Delta).

The strains of interest present mutations on the spike protein, which often results in altered virus comportment and may lead to immune escape ^[1][5][6][2,7,11].

Therefore, comprehensive knowledge of the current prophylactic and treatment schemes for COVID-19 is of the utmost importance to preparing efforts to fight disease dissemination.

As the pandemic evolved, so did the search for potential prophylactic and therapeutic agents (Figure 1).

Vaccines have undoubtedly conquered the research space to prevent SARS-CoV-2 because of their advantages in the prophylaxis of COVID-19. Besides that, some therapies have also been considered against COVID-19. Many of these therapies have emerged from drug repurposing. Repurposing of a drug consists of using an existing medicine with a new therapeutic purpose beyond its primary indications ^{[1][7][8][9][10]}[7,12,13,14,15].

Table 1 summarizes the currently available therapies against COVID-19 and their main underlying action mechanisms.

The spread of COVID-19 has mobilized research and development (R&D) efforts. Therefore, several approaches for vaccine development against COVID-19 have been tested, such as inactivated virus, live attenuated, recombinant protein, adenovirus vector, influenza virus vector, as well as mRNA and DNA vaccines. As a revolutionary innovation, mRNA vaccine technology has uniquely controlled the COVID-19 pandemic ^[14][19].

Briefly, mRNA vaccines are composed of a vehicle, particularly lipid nanoparticles, that enables the delivery of a nucleic acid molecule encoding the antigen of interest. In the case of SARS-CoV-2, the spike protein is delivered into the target cell in the human host, allowing the host cell to produce the target protein and express the antigen to elicit an immune response ^[14][19].

Currently, two mRNA-based vaccines are approved against COVID-19: Comirnaty (BNT162b2) and Spikevax (mRNA-1273) ^[15][20]. According to the literature, mRNA technology is desirable as it works as a template for protein translation and does not require bioreactors. It reduces the risk of bacterial contamination and makes scaling up less challenging. Moreover, mRNA vaccines reduce the risk of immunogenicity compared to other viral vector-based modalities. However, the dependency on cold-chain storage and transport may hamper their global applications ^[15][20].

Given the clinical picture presented by patients with SARS-CoV-2, another potential therapy is antiviral drugs such as remdesivir (REM), favipiravir (FPV), and lopinavir/ritonavir, which will be described in more detail later in the manuscript.

In brief, these drugs can inhibit the entry of the virus by targeting the type-II transmembrane serine protease (TMPRSS2) and the ACE-2 receptor. They may also interfere with endocytosis or with the action of RNA-dependent RNA polymerase (RdRp) and the SARS-CoV-2 3-chymotrypsin-like protease (3CLpro) through fusion inhibitors.

Despite the promising prospects for this therapeutic class, some groups of antiviral drugs remain to be explored to treat COVID-19 ^[16][17][21,22].

The convalescent plasma of patients who have recovered from COVID-19 presents neutralizing antibodies in its constitution, which can fight infection by minimizing the inflammatory response ^[12][17]. The reduction in the inflammatory response may happen due to viremia suppression contributing to prophylaxis and recovery.

The administration of passive antibodies may be an option to achieve rapid immunity ^[9][14].^. In theory, the administration of convalescent plasma should be completed at an early stage for superior efficacy ^[18][23]. However, its application continues to be controversial ^[19][24].

Monoclonal antibodies (mAbs) have effectively prevented and treated various viral infections ^[20][25]. Currently, potent neutralizing mAbs have been investigated against COVID-19, by targeting the receptor-binding domain (RBD) of the spike glycoprotein of SARS-CoV-2, blocking the binding between the S protein and the host receptor, ACE2 ^[21][22][26,27]. Moreover, other neutralizing mAbs can mediate viral activity by targeting nonblocking epitopes of the RBD or N-terminal domain (NTD) of the spike protein ^[23][24][28,29]. Some neutralizing antibodies studied against COVID-19 have been reviewed previously ^[25][30].

However, the emergence of new virus strains with mutations in the protein epitopes may hinder the application of these selective immunotherapies.

Therefore, to overcome mutational virus escape, cocktail therapies aiming at administering antibodies targeting multiple epitopes on the spike protein have been investigated. Nevertheless, these treatment approaches may be challenging and considerably increase manufacturing costs ^[26][31].

Recently, the emergence of bispecific mAbs (bsAbs) has gained interest for the treatment of COVID-19 as one molecule can target two different antigen-binding sites ^[26][31]. However, the use of these approaches remains to be fully explored.

Although applying mAb-based interventions against SARS-CoV-2 may require periodic updates due to the shifting antigenic landscape, the potential passive immunization in persons with a high risk of ineffective responses is a significant leap forward in the fight against viral evolution ^[27][32].

Interferons (IFNs) induce the encoding of several proteins that can inhibit viral replication by decreasing cellular metabolism, interfering with the membrane formation necessary for virus replication, and inducing the release of cytokines that promote adaptive immunity. There are three families of IFNs, but only type I and type III are produced when the immune system detects the presence of viral nucleic acids. IFN-α belongs to type I, as well as INF-β, and fights coronaviruses by inhibiting virus replication ^[12][20][17,25].

According to Sodeifian et al. ^[28][33], it is paramount to establish the best time window to prescribe this type of treatment, as evidence has revealed that the administration of INF before the viral peak and the inflammatory phase of the illness could offer a highly protective effect. On the contrary, the administration of IFN during the inflammatory and severe phase of the disease may cause immunopathology and long-lasting harm for patients ^[28][33].

Corticosteroids are readily available agents extensively used as anti-inflammatory agents against respiratory infections. However, evidence has suggested that no clear benefits have been observed regarding their application in SARS and MERS patients. Therefore, their application in the initial phase of the COVID-19 pandemic was not recommended ^[29][34].

Later, due to preliminary data demonstrating lower mortality in patients with COVID-19 treated with corticosteroids, the use of corticosteroids for treating patients with severe or critical COVID-19 has been recommended ^[30][35].

Corticosteroids may play a pleiotropic role in different pathophysiological components in severe COVID-19 ^[31][36]. One of the studied drugs is dexamethasone (DEX), a synthetic glucocorticoid  ^[12][17].